{
  "id": 19486629,
  "title": "Spirax-Sarco shares gain 4% on improved sales growth",
  "url": "https://urgent.news/2026/11/11/spirax-sarco-shares-gain-4-on-improved-sales-growth",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T11:04:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/spiraxsarco-shares-gain-4-on-improved-sales-growth-93CH-5018321"
  },
  "original_language": "en",
  "account": "Spirax-Sarco Engineering's shares rose by 4% on Wednesday following the company's announcement of improved sales performance and higher margins. During the ten months ending October 31, the engineering firm achieved organic sales growth and an adjusted operating profit margin that outpaced its first-half results. The company reaffirmed its guidance for mid-single-digit organic growth in total revenues for the year and an adjusted operating profit margin above 20.0% by the end of 2025.\n\nSteam Thermal Solutions, one of the company's divisions, recorded organic sales growth in the first quarter of 2025 that surpassed first-half levels. This growth was fueled by larger orders and sustained demand. The division anticipates second-half margins to exceed those of the first half, which should lead to a full-year margin aligned with the 2025 target. China's sales, constituting about 15% of Steam Thermal Solutions' total sales in 2025, are expected to match the levels of 2025 throughout the year.\n\nElectric Thermal Solutions also maintained robust organic sales growth during the four months leading up to October. The division reported significant order intake across sectors, including Process Heating, Heat Trace, and Equipment Heating. Notably, excluding semiconductor sales, which accounted for roughly 13% of Electric Thermal Solutions' 2025 revenue, organic sales growth remained above the company's mid-single-digit medium-term objective.\n\nWatson-Marlow Fluid Technology Solutions demonstrated a rise in organic sales growth within the Biopharm segment during the first quarter compared to the preceding half of the year. The division continued to see orders outpace sales, and it also experienced strong organic sales growth in the Process Industries segment, bolstered by market share advancements. At October 31, the company's net borrowings, excluding leases, amounted to £541.6 million, a decline from £618.2 million as of June 30. The company's net debt to EBITDA ratio improved to 1.3x from 1.6x. The company projects a cash conversion rate of approximately 90% for the full year.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}